What is Carrick Therapeutics?
Founded in 2016, Carrick Therapeutics operates at the intersection of advanced molecular biology and precision medicine. Unlike traditional pharmaceutical models that often rely on single-compound strategies, Carrick employs a multi-faceted approach to oncology. The company integrates cutting-edge diagnostic technologies with a deep mechanistic understanding of cancer resistance, allowing for the identification of specific patient populations most likely to benefit from their novel treatments. This strategic focus on the underlying drivers of disease positions the firm as a leader in the development of next-generation cancer therapies, effectively bridging the gap between laboratory innovation and clinical application.
How much funding has Carrick Therapeutics raised?
Carrick Therapeutics has raised a total of $149.5M across 3 funding rounds:
Series A
$95M
Series C
$19.5M
Other Financing Round
$35M
Series A (2016): $95M with participation from ARCH Venture Partners, Lightstone Ventures, Evotec AG, Woodford Investment Management, Cambridge Enterprise, Cambridge Innovation Capital, and Google Ventures
Series C (2022): $19.5M led by Evotec, Rosetta Capital, Arch Venture Fund, GV, and Lightspeed Venture Partners
Other Financing Round (2022): $35M supported by Pfizer
Key Investors in Carrick Therapeutics
ARCH Venture Partners
A leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists to commercialize university-led innovations.
GV
A global venture capital firm that invests across multiple stages and sectors, focusing on life sciences, enterprise solutions, and frontier technology innovations.
Lightstone Ventures
A specialized firm that backs founders turning cutting-edge science into new therapies, providing the capital and industry connections necessary to transform lab ideas into medical treatments.
What's next for Carrick Therapeutics?
With the recent infusion of capital, Carrick Therapeutics is well-positioned to accelerate its clinical development programs and expand its proprietary research platform. The company's strategic roadmap emphasizes the transition from early-stage discovery to more advanced clinical trials, focusing on validating its first-in-class candidates in human subjects. As the firm scales its operations, the focus will likely shift toward optimizing its data-driven multimodality platform to identify new therapeutic targets. By maintaining strong partnerships with its diverse investor base, Carrick is poised to navigate the complexities of the biotech landscape, aiming to deliver transformative outcomes for patients facing the most challenging forms of cancer.
See full Carrick Therapeutics company page
